50 results about "Phospholipase A2" patented technology

The invention discloses antioxidant salmon collagen peptide and a preparation method thereof, and belongs to the technical field of processing of salmon collagen peptide. The preparation method comprises the following steps: firstly, carrying out enzymolysis on the salmon material by using phospholipase A2, hydrolyzing abundant membrane phospholipids in the salmon material, destroying fat cell structures and releasing wrapped triglyceride, then carrying out secondary enzymolysis by using aspergillus oryzae lipase, hydrolyzing macromolecular lipids into free fatty acids which are easily dissolved in supercritical carbon dioxide, and carrying out secondary enzymolysis by using aspergillus oryzae lipase. The degreased salmon material is obtained by means of supercritical carbon dioxide extraction, the lipid removal rate is greatly increased, and the antioxidant salmon collagen peptide which is small in molecular weight and high in oxidation resistance is obtained through subsequent collagen extraction and enzymolysis.

The invention discloses a leontopodium alpinum callus extract as well as a preparation method and application thereof, and belongs to the technical field of plant active ingredient extraction. The leontopodium alpinum callus extract is prepared by the following steps: mixing leontopodium alpinum callus freeze-dried powder with a buffer solution, adding cellulase, pectinase and beta-glucanase, uniformly mixing, reacting to obtain primary enzymolysis slurry, adjusting the primary enzymolysis slurry to be neutral, adding phospholipase A2, stirring, reacting to obtain deep enzymatic hydrolysate, filtering, washing, and drying to obtain the leontopodium alpinum callus extract. Transferring into an extraction kettle, adding an entrainer, and extracting to obtain a leontopodium alpinum extract; dissolving soybean phospholipid and cholesterol in ethanol to obtain an organic phase; dispersing the leontopodium alpinum extract in a buffer solution to obtain an active matter water phase; and injecting the organic phase into the active matter water phase, stirring, carrying out reduced pressure distillation, and homogenizing. The preparation method provided by the invention can efficiently and completely obtain the active component, and the nano-liposome formed by phospholipid molecules can effectively improve the stability of the active component.

The invention relates to the technical field of bioengineering, in particular to a preparation process for extracting antihypertensive peptide from euphausia superba. The process comprises the following steps: adding a ferulic acid / arginine double-grafted pullulan compound in a preparation process, and breaking an emulsification interface by utilizing beta-cyclodextrin adsorption and phospholipase A2 cracking to obtain a soluble pretreatment product; meanwhile, short-time round-trip pH pulse is implemented in the incision enzyme hydrolysis process to activate potential enzyme cutting sites, finally, hydrophobic aggregation peptides are removed through weak acid rapid elution, and excision hydrolysis is performed to obtain a target product with the molecular weight of 0.5-3 kDa, so that dynamic induction and antioxidant steady-state dual control of hydrolysis reaction is realized; the generation proportion of short peptides and the ACE inhibition persistence are improved, and the flavor and the storage stability are remarkably improved. The method is controllable in technological process, high in repeatability and suitable for large-scale preparation of the euphausia superba protein functional peptide and development and application of antihypertensive food.

The application belongs to the technical field of biological detection, and discloses a cardiovascular marker control article and a preparation method thereof. The cardiovascular marker control article comprises a serum matrix, antigens, a preservative and a stabilizer. The antigens include cardiac troponin I antigens, creatine kinase isoenzyme antigens, myoglobin antigens, amino-terminal brain natriuretic peptide precursor antigens, brain natriuretic peptide antigens, D-dimer antigens, heart-type fatty acid-binding protein antigens, myeloperoxidase antigens and lipoprotein phospholipase A2 antigens. The stabilizer includes at least one of D-trehalose, sucrose, glycine, inositol and polyethylene glycol. The cardiovascular marker control article can cover various cardiovascular disease markers, including heart failure, pulmonary embolism, vasculitis and atherosclerosis, myocardial injury, myocardial infarction and the like. The control article can be used as a third-party control article for indoor and inter-laboratory quality control of a cardiovascular disease screening and auxiliary diagnosis measurement system.

This invention relates to nucleic acid aptamers for lipoprotein-associated phospholipase A2 (Lp-PLA2), wherein the nucleic acid aptamer is at least one of B76-2, B76-4, and B76-5, with sequences shown in SEQ ID NO.1, SEQ ID NO.2, and SEQ ID NO.3, respectively. The Lp-PLA2 aptamers provided by this invention fill a gap in the field of Lp-PLA2 aptamers and exhibit high affinity and specificity. Three aptamers with good affinity and specificity for Lp-PLA2 have been screened and verified. These aptamers can be formulated into molecular probes or used as detection reagents in methods or kits for detecting Lp-PLA2, improving accuracy. They can also be used to develop novel Lp-PLA2 biosensing methods for molecular identification, showing great application potential in the early warning of cardiovascular disease events.

The present disclosure relates to improved methods for the enzymatic hydrolysis of phospholipids in egg yolks. Phospholipase A2 enzymes hydrolyze egg yolk phospholipids at the sn-2 fatty ester group to liberate the corresponding free fatty acids. The rate of enzymatic hydrolysis and the degree to which free fatty acids are liberated can be increased by addition of one or more calcium salts. The use of calcium salts to increase egg yolk phospholipid hydrolysis rate decreases production costs, decreases processing and production times, and increases process safety by reducing microbial content in enzyme-modified egg yolks.

Provided is a composition for preparing a medicament for treating diabetic peripheral neuropathy. The pharmaceutical composition comprises cobra venom phospholipase A2, or a combination of cobra venom phospholipase A2 and at least one additional drug for treating diabetic peripheral neuropathy. The diabetic peripheral neuropathy is characterized by a slowdown in motor nerve conduction velocity and / or sensory nerve conduction velocity of a patient, and / or hypoesthesia or loss of sensation in both lower limbs. The pharmaceutical composition can be used to ameliorate the clinical symptoms described above in patients with diabetic peripheral neuropathy, and belongs to the field of biopharmaceuticals.

The application provides a lipoprotein phospholipase A2 determination kit for latex immunoturbidimetry, which contains reagent R1 and reagent R2; the reagent R1 comprises the following components: buffer, inorganic salt, anti-interference additive, surfactant and Proclin 300; the reagent R2 comprises the following components: buffer, lipoprotein phospholipase A2 antibody coated latex microspheres, stabilizer, surfactant and Proclin 300. The kit is a liquid kit with strong stability, high accuracy, wide linear range and strong anti-HOOK capability.

Provided herein are highly transformable maize plants, referred to as HI-NA plants, and methods of their production and use. A HI-NA plant, as disclosed herein, is homozygous for a loss-of-function mutant allele in the patatin-like phospholipase A2α (MATL) gene and at least heterozygous for one or more QTL and / or gene alleles that are responsible for increased haploid induction and / or transformation frequency in plants. A HI-NA plant, as disclosed herein, may also have a cytotype A background, which may render it highly transformable. Also provided are methods of producing I-NA plants and methods of using a HI-NA plant for editing plant genomic DNA.

The present invention relates to a pharmaceutical composition. The pharmaceutical composition comprises cobra cardiotoxin (CDX) and a pharmaceutically acceptable carrier thereof. The pharmaceutical composition is further characterized by comprising use of cobra cardiotoxin (CDX) in combination with any one or both of the following drugs for treating migraine: cobra phospholipase A2 (PLA2) and cobra neurotoxin (NTX). The pharmaceutical composition can be used for preventing and treating migraine and down-regulating the concentration of nitric oxide (NO) in migraine patients. The pharmaceutical composition is of great significance for the treatment of migraine.

The object of the present invention is to provide a reaction substrate of human lipoprotein-associated phospholipase A2 protein. Another object of the present invention is to provide a biochemical kit for detecting human lipoprotein-associated phospholipase A2 protein. In order to achieve the above-mentioned purpose, the present invention provides a reaction substrate for human lipoprotein-associated phospholipase A2 protein. The present invention prepares a substrate, dissolves the synthesized substrate 1-dodecyl-2 (4-nitrophenylglutaryl) phosphatidylcholine in TE buffer, and adds glycerol containing silicone oil as a stabilizer. In order to further improve the substrate stability, the present invention uses trifluoropropyl methyl silicone oil after testing. After testing, the substrate of this formula was accelerated to destroy stability at 55°C for 7 days, and the concentration of 4-nitrophenol was not increased after testing. After adding human lipoprotein-associated phospholipase A2 protein, the efficiency of the 4-nitrophenol concentration reaction curve was not decreased, and the stability of the reaction substrate of human lipoprotein-associated phospholipase A2 protein was improved.

The present invention relates to a drug combination, the drug composition comprises cobra cardiotoxin (CDX) and a pharmaceutically acceptable carrier thereof, and the drug composition is also characterized in that it further comprises cobra cardiotoxin (CDX) and any one of other drugs for treating migraine, cobra phospholipase A2 (PLA2) and cobra neurotoxin (NTX), or a combination of both. The drug composition can be used to prevent and treat migraine, and lower the concentration of nitric oxide (NO) in the body of a migraine patient, which is of great significance for the treatment of migraine.

The invention relates to the technical field of biology, in particular to an anti-PLA2R fully human IgG monoclonal antibody and application thereof. The invention provides a human-derived anti-alkali phospholipase A2 receptor antibody PLA2R PL82 screened by using a phage surface display technology, the subtype of the human-derived anti-alkali phospholipase A2 receptor antibody PLA2R PL82 is IgG4, and amino acid sequences of light chain and heavy chain variable regions of the human-derived anti-alkali phospholipase A2 receptor antibody PLA2R PL82 are respectively shown as SEQ ID NO: 6 and SEQ ID NO: 7. The antibody can specifically recognize an alkali phospholipase A2 receptor, the reactivity, the stability and the matrix effect all meet the performance use requirements of a kit, and the antibody plays an important role in alkali phospholipase A2 IgG project application as a quality control product.

The invention discloses an AuPdNPs (at) GO-MWCNTs composite material modified immunosensor with a wide detection range and application of the AuPdNPs (at) GO-MWCNTs composite material modified immunosensor, the composite material is prepared by dispersing graphene oxide and carboxylated MWCNTs in a solution, performing an ultrasonic reaction in an ice-water bath to obtain a GO-MWCNTs compound, then dropwise adding an AuPdNPs solution onto a GO-MWCNTs film, and after the AuPdNPs solution is air-dried, forming the AuPdNPs (at) GO-MWCNTs composite material. The detection limit of the immunosensor modified by the AuPdNPs (at) GO-MWCNTs compound on lipoprotein phospholipase A2 is 0.3 ng / ml, and the detection range is 1 ng / ml to 2 [mu] g / ml; and the method has good specificity, the repeatability, the stability and the clinical property all meet the requirements, and the content of the lipoprotein phospholipase A2 in a clinical sample can be quantitatively detected.

The invention belongs to the technical field of medicine separation, and particularly relates to magnetic bead immobilized snake venom phospholipase A2 as well as a preparation method and application thereof. The preparation method comprises the following steps: carrying out a coupling reaction on ferroferric oxide nanoparticles and (3-aminopropyl)-triethoxysilane in an organic solvent, washing, and drying to obtain aminated magnetic beads; and activating the aminated magnetic beads with glutaraldehyde, incubating with a snake venom phospholipase A2 solution, and reacting to obtain the magnetic bead immobilized snake venom phospholipase A2. The magnetic bead immobilized snake venom phospholipase A2 prepared by the invention can be used for rapidly and accurately fishing the snake venom phospholipase A2 toxin antidote from a mixture system, and has a better application prospect in the field of snake venom antidote research.

The present invention provides a biomarker for the detection of glioma microenvironment (TME), comprising a serum marker selected from any one or more of annexin A1 (ANXA1), annexin A2 (ANXA2), matrix metalloproteinase 14 (MMP14) and potential transforming growth factor beta binding protein 2 (LTBP2), and a pathological marker selected from any one or more of Annexin A1 (ANXA1), Annexin A2 (ANXA2), matrix metalloproteinase 14 (MMP14) and potential transforming growth factor beta binding protein 2 (LTBP2); the pathological marker is selected from one or more of periostin (POSTN), lactoferrin (LTF) and a phospholipase A2 group IIA (PLA2G2A), and the pathological marker is selected from one or more of periostin (POSTN), lactoferrin (LTF) and phospholipase A2 group IIA (PLA2G2A). The invention also provides an application of the biomarker in diagnosis of glioma. The invention provides an innovative idea and a biomarker for non-invasive diagnosis of glioma, and can be used for prognosis and malignant diagnosis of glioma.

The invention discloses an application of lysopc16: 0 and / or PPAR gamma and / or phospholipase A2 as a target spot in preparation of an endometriosis related treatment preparation, relates to the technical field of biological medicines, and provides an application of lysopc16: 0 and / or PPAR gamma and / or phospholipase A2 as a target spot in preparation of an endometriosis related treatment preparation. The invention relates to application of an inhibitor of lysopc16: 0 and / or PPAR gamma and / or phospholipase A2 in preparation of a medicine for treating endometriosis. The inhibitor is a PPAR (peroxisome proliferator activated receptor) gamma antagonist for blocking a lysopc16: 0 mediated PPAR gamma signal channel. The PPARgamma antagonist comprises GW9662, T0070907, MM902 and SR1664, and the PPARgamma antagonist comprises GW9662, T0070907, MM902 and The diagnosis accuracy of the endometriosis is improved through the target point of the lysopc16: 0, and the inhibitor of the lysopc16: 0 and / or the PPAR gamma and / or the phospholipase A2 can be used in the medicine for treating the endometriosis.

The invention discloses a streptomyces purpureus phospholipase A2 mutant and application thereof, and belongs to the technical field of biology. According to the invention, six mutants with single point mutation and five combined mutants are obtained; compared with the wild type, the enzyme activities of the mutants N21E, Q47K, F53H, Y68H, I84L, Q116M, N21E / I84L, Q47K / I84L, I84L / Q116M, N21E / I84L / Q116M and Q47K / I84L / Q116M are improved by 32.3%, 20.2%, 27.9%, 20.5%, 69.7%, 60.5%, 106.6%, 92.9%, 213.2%, 406.5% and 304.3% respectively. The enzyme activity of the phospholipase A2 mutant obtained by the invention is obviously improved, and the phospholipase A2 mutant has great industrial application potential and economic value.

The invention discloses application of a MarR family transcriptional regulation factor SCLAV2489 (GeneBank numbering EFG07562.1) or a phospholipase A2 gene SCLAV4219 (GeneBank numbering EFG09293.1) as a target in improving the fermentation yield of clavulanic acid, the MarR family transcriptional regulation factor SCLAV2489 or the phospholipase A2 gene SCLAV4219 in a streptomyces clavuliformis genome is inactivated or knocked out, so that the fermentation yield of clavulanic acid of a mutant strain can be remarkably improved, and the industrial application prospect is achieved.

The invention discloses egg yolk powder with phospholipid enzymolysis synergistic interface steady-state protection and a preparation method of the egg yolk powder, and belongs to the technical field of creation of high-quality egg yolk powder. Carrying out phospholipase A2 controllable enzymolysis pretreatment on the egg yolk liquid under the protection of nitrogen; performing micro-emulsification steady-state construction on the compound colloid of the Arabic gum and the beta-cyclodextrin; and carrying out temperature-controlled spray drying on the pretreatment liquid. The key processes are coupled to form a steady-state pretreatment scheme for actively reconstructing a lipid dispersion state from a molecular level, so that the passive defect that oxidation deterioration cannot be fundamentally inhibited due to the fact that a traditional process only depends on later packaging or external addition of an antioxidant is overcome, and the egg yolk powder with low surface free fat coverage rate (SFCR is less than or equal to 3.5%) is produced. After the product is stored for 90 days in an accelerated manner, the peroxide value growth rate (delta POV) is less than or equal to 60.0%, the key smelly aldehyde total concentration (TCKA) is less than or equal to 2.5 mu g / kg, and the emulsifying activity index retention rate is greater than or equal to 85.0%.

The invention discloses a flavoring agent for branched chain amino acid and a preparation method of the flavoring agent, and belongs to the technical field of food additives. The flavoring agent comprises a flavoring component and a composite lipid carrier coating the core component, wherein the lipid carrier is composed of phospholipid, auxiliary lipid and a structure enhancer. By introducing high-melting-point phytosterol, a soft-hard alternate microscopic phase separation structure is constructed in a flexible phospholipid bimolecular layer, on one hand, the structure provides compact physical barrier by utilizing a rigid framework formed by phytosterol, the oxidation resistance and the humidity resistance of the flavoring component are remarkably improved, and the stability of the shelf life is ensured; and on the other hand, a phospholipid region is reserved as an enzymolysis target, and the carrier is structurally disintegrated within 45 seconds when being in contact with saliva and releases the flavoring component in a pulse manner by utilizing the specific shearing action of oral cavity phospholipase A2.

The present invention discloses a phospholipase A2 mutant from Streptomyces rhodochrous and its application, belonging to the field of biotechnology. Six single-site mutation mutants and five combined mutants were obtained. Compared with the wild type, the enzyme activities of the mutants N21E, Q47K, F53H, Y68H, I84L, Q116M, N21E / I84L, Q47K / I84L, I84L / Q116M, N21E / I84L / Q116M, and Q47K / I84L / Q116M were all improved by 32.3%, 20.2%, 27.9%, 20.5%, 69.7%, 60.5%, 106.6%, 92.9%, 213.2%, 406.5%, and 304.3%, respectively. The phospholipase A2 mutants obtained by the present invention have significantly improved enzyme activity and have great industrial application potential and economic value.

The invention discloses phospholipase A2 inhibitory proteins PLI1 and PLI2 as well as a gene for coding the phospholipase A2 inhibitory proteins PLI1 and PLI2 and application thereof, and belongs to the technical field of gene engineering. In the implementation scheme, the recombinant phospholipase A2 inhibitory protein obtained through a gene shuffling technology is described, the two phospholipase A2 inhibitory proteins PLI1 and PLI2 are screened out through a phage display technology, compared with the inhibitory protein before shuffling, the two phospholipase A2 inhibitory proteins PLI1 and PLI2 still have the good inhibitory effect and activity, and one of the two phospholipase A2 inhibitory proteins PLI1 and PLI2 is obviously superior to the inhibitory protein before shuffling. The invention also comprises polynucleotide for coding the protein and a recombinant vector containing the polynucleotide, and the protein is suitable for preparing the snake venom inhibitor, has broad spectrum and high activity, is expected to realize large-scale mass production, and has wide application prospects.

The invention discloses a cardiovascular event risk index calculation method, and relates to the technical field of medical information, and the method comprises the following steps: determining whether a to-be-evaluated patient meets an application condition or not according to a preset inclusion standard; for a patient meeting the standard, collecting a peripheral blood sample of the patient, carrying out centrifugal treatment, and separating to obtain a serum or plasma sample; s2, quantitatively measuring four serological indexes, namely lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, homocysteine and serum amyloid protein A, of the serum or plasma sample obtained in the step S1 by using an authenticated laboratory detection method; s2, calculating a cardiovascular risk index by using a cardiovascular risk calculation formula based on the four index values measured in the step S2; s3, according to the cardiovascular risk index value calculated in the step S3, dividing the cardiovascular event risk of the patient into three levels of low risk, medium risk and high risk; and S4, generating a structured risk assessment report according to the risk grading result obtained in the step S4, and outputting the structured risk assessment report.

The invention relates to the technical field of biology, in particular to a method for extracting soybean lecithin from soybean phospholipid. The method comprises the following steps: carrying out first stirring treatment on a first mixture obtained by mixing soybean phospholipid and acetone to obtain a solid soybean phospholipid crude extract; carrying out second stirring treatment on a second mixture obtained by mixing the solid soybean phospholipid crude extract and ethanol to obtain a soybean phospholipid crude extract, and concentrating the soybean phospholipid crude extract to obtain a concentrated solution; carrying out enzymolysis on the concentrated solution by using a compound enzyme to obtain a soybean lecithin concentrated solution, the compound enzyme being composed of phospholipase A2, lipase and protease; and carrying out enzyme deactivation treatment and drying treatment on the soybean lecithin concentrated solution to obtain the soybean lecithin. According to the method, the yield and purity of the soybean lecithin can be effectively improved, and the extracted soybean lecithin has a high moisture retention rate and has a wide application prospect in the food industry.

The invention provides combination therapy involving the inhibition of lipoprotein-associated phospholipase A2 (Lp-PLA2) and a second therapy. To facilitate the practice of the invention, the invention also provides a composition comprising a first agent comprising an Lp-PL2 inhibitory molecule, a second agent, and a pharmaceutically-acceptable carrier. In certain embodiments, the second agent comprises an amyloid-targeting molecule, an agent that lowers the level of amyloid in the brain or body, a tau-targeting molecule, a vasculature-targeting molecule, an inflammation-targeting molecule, and / or a molecule that modulates a mechanism of action that is orthogonal from Lp-PLA2 inhibition. Combinations of such second agents are contemplated as well. While the invention can be used as prophylaxis and treatment for a variety of disorders, in certain embodiments, the invention is employed against vascular damage or inflammation associated with a disease, condition, or therapy-related side effect, particularly in the context of neurological or neuromuscular conditions.

A system for the production of soluble Trypanosoma Brucei gambiense phospholipase A2 (TbgPLA2), consisting of: a bioinformatics analysis unit configured to predict the 3D structure, topology, and signal peptide positions of TbgPLA2; a gene construct manufacturing unit configured to produce codon-optimized TbgPLA2 gene constructs with removed signal peptide and transmembrane sequences; an expression unit configured to express the TbgPLA2 constructs in host cells selected from the group consisting of E. coli and Pichia Pfarrer; a purification unit configured to purify TbgPLA2 from soluble fractions and inclusion bodies using nickel column metal affinity chromatography; and a refolding unit configured to renature TbgPLA2 using optimized buffer conditions consisting of Tris 55 mM, NaCl 21 mM, KCl 0.88 mM at pH 8.2.

To provide a composition or the like for inhibiting infiltration of pro-inflammatory macrophages.SOLUTION: The composition comprises phospholipase A2, one of the main components of bee venom, as an active ingredient. In addition, a health functional food composition and a feed composition for inhibiting infiltration of pro-inflammatory macrophages comprising phospholipase A2 as an active ingredient are also provided.SELECTED DRAWING: Figure 1A

The present invention relates to the technical field of light industrial grease. Specifically disclosed are a preparation method for and a use of a medium-chain triglyceride. In the present invention, firstly, specific chemical modification is performed on phospholipase A2 by using EDC or a modification solution prepared by mixing EDC with iodoacetamide to obtain modified phospholipase A2; the modified phospholipase A2 is used as a catalyst for catalyzing a hydrolysis reaction of coconut oil; specific hydrolysis is performed to enrich C8 and C10 fatty acids, and then esterification is performed on the fatty acids and glycerol to form the medium-chain triglyceride. The chemically specifically modified phospholipase A2 of the present invention exhibits improved hydrolysis specificity for C8 and C10 fatty acids in coconut oil, so that a light-phase component having a high content of C8 and C10 fatty acids is obtained after molecular distillation of a hydrolysate; and by means of subsequent esterification with glycerol, the medium-chain triglyceride having a C8 and C10 content of up to 95% can be obtained. The medium-chain triglyceride can be used in the fields of food, nutrition, medicine, etc.

This invention relates to the field of monoclonal antibody technology, and in particular to a monoclonal paired antibody for lipoprotein-associated phospholipase A2 and its applications. The heavy chain sequence of the first antibody is shown in SEQ ID NO:1, and its light chain sequence is shown in SEQ ID NO:2; the heavy chain sequence of the second antibody is shown in SEQ ID NO:3, and its light chain sequence is shown in SEQ ID NO:4. The monoclonal paired antibody for lipoprotein-associated phospholipase A2 of this invention exhibits high specificity and sensitivity, providing accurate and reliable reagent support for relevant detection scenarios. It can be used in multiple detection fields, including biochemical immunoturbidimetric assays, immunochromatographic assays, and ELISA, achieving rapid, efficient, and highly sensitive clinical detection of lipoprotein-associated phospholipase A2 antigen in serum.